BioXcel Therapeutics, Inc. — Director's Dealing 2023

May 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2023-05-14

Reporting Person: Rodriguez Javier (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-14	Common Stock	M	5000	—	Acquired	6135	Direct
2023-05-15	Common Stock	S	1785	$27.3192	Disposed	4350	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-14	Restricted Stock Units	$	M	5000	Disposed		Common Stock (5000)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2022.

F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $27.00 to $27.63. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F4: On May 14, 2022, the Reporting Person was granted 5,000 RSUs that vested and settled on May 14, 2023.